Literature DB >> 26267013

Fibrosis markers, hip fracture risk, and bone density in older adults.

J I Barzilay1,2, P Bůžková3, J R Kizer4, L Djoussé5, J H Ix6, H A Fink7, D S Siscovick8, J A Cauley9, K J Mukamal10.   

Abstract

UNLABELLED: We examined whether blood levels of two markers of fibrosis (transforming growth factor beta one (TGF-β1) and procollagen type III N-terminal propeptide (PIIINP)) are related to hip fracture risk and to bone mineral density (BMD). TGF-β1 levels were associated with lower hip fracture risk in women and with lower BMD in men. PIIINP levels were not associated with either outcome.
INTRODUCTION: TGF-β1 serves several roles in bone formation and resorption. A consequence of TGF-β1 activation is the production of PIIINP, a marker of collagen III deposition. Here, we explore whether these two biomarkers are related to incident hip fracture and bone mineral density (BMD) and whether their associations are modified by systemic inflammation, as measured by C-reactive protein (CRP) levels.
METHODS: Participants were from the Cardiovascular Health Study (mean age 78 years; mean follow-up 8.3 years). We included 1681 persons with measured levels of TGF-β1 (149 hip fractures) and 3226 persons with measured levels of PIIINP (310 hip fractures).
RESULTS: Among women, higher TGF-β1 levels were associated with lower hip fracture risk (HR, per doubling, 0.78 [95 % CI 0.61, 0.91]). Among men, TGF-β1 levels were associated with hip fracture risk in a non-linear manner, but among those with elevated CRP levels, doubling was associated with increased risk of fracture (HR 2.22 [1.20, 4.08]) (p = 0.02, interaction between low and high CRP and TGF-β1 on fracture risk). TGF-β1 levels had no significant association with total hip or total body BMD in women but were significantly associated with lower BMD in men. There were no associations of PIIINP levels with hip fracture risk or BMD in men or women.
CONCLUSIONS: TGF-β1 levels appear to be associated with bone-related phenotypes in a sex-specific manner. The reasons for these differences between men and women regarding TGF-β1 levels and hip fracture risk and bone density require further investigation.

Entities:  

Keywords:  Bone mineral density; Hip fracture; PIIINP; TGF-β

Mesh:

Substances:

Year:  2015        PMID: 26267013      PMCID: PMC7060924          DOI: 10.1007/s00198-015-3269-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  16 in total

Review 1.  TGF-beta in blood: a complex problem.

Authors:  D J Grainger; D E Mosedale; J C Metcalfe
Journal:  Cytokine Growth Factor Rev       Date:  2000 Mar-Jun       Impact factor: 7.638

Review 2.  Regulation of postnatal bone homeostasis by TGFβ.

Authors:  Simon Y Tang; Tamara Alliston
Journal:  Bonekey Rep       Date:  2013-01-09

3.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

Review 4.  Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events.

Authors:  Johan Sundström; Ramachandran S Vasan
Journal:  Curr Opin Lipidol       Date:  2006-02       Impact factor: 4.776

5.  The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis.

Authors:  A J Borton; J P Frederick; M B Datto; X F Wang; R S Weinstein
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

6.  Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing.

Authors:  Tae-Joon Cho; Louis C Gerstenfeld; Thomas A Einhorn
Journal:  J Bone Miner Res       Date:  2002-03       Impact factor: 6.741

7.  Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study.

Authors:  Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djousse; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Sicovick; Russell P Tracy; Kenneth J Mukamal
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-06-24

8.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

9.  Relationship between serum TGF-β1, OPG levels and osteoporotic risk in native Chinese women.

Authors:  Gen-Qing Xie; Dan-Dan Lei; Hong-Bo He; Jia-Ji Gong; Chao Chen; Peng Chen; Hong Zhang; Xiang-Hang Luo; Er-Yuan Liao; Xian-Ping Wu
Journal:  Clin Chim Acta       Date:  2013-05-02       Impact factor: 3.786

10.  Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.

Authors:  A Erlebacher; R Derynck
Journal:  J Cell Biol       Date:  1996-01       Impact factor: 10.539

View more
  3 in total

1.  Higher albumin:creatinine ratio and lower estimated glomerular filtration rate are potential risk factors for decline of physical performance in the elderly: the Cardiovascular Health Study.

Authors:  Petra Bůžková; Joshua I Barzilay; Howard A Fink; John A Robbins; Jane A Cauley; Joachim H Ix; Kenneth J Mukamal
Journal:  Clin Kidney J       Date:  2019-03-21

2.  Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: The Cardiovascular Health Study.

Authors:  Emily A Rosenberg; Petra Bůžková; Howard A Fink; John A Robbins; Molly M Shores; Alvin M Matsumoto; Kenneth J Mukamal
Journal:  Metabolism       Date:  2020-10-12       Impact factor: 13.934

3.  Analysis of fracture healing in osteopenic bone caused by disuse: experimental study.

Authors:  A G Paiva; G R Yanagihara; A P Macedo; J Ramos; J P M Issa; A C Shimano
Journal:  Braz J Med Biol Res       Date:  2016-02-02       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.